Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Procter & Gamble Co — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.96 (market cap $1.74B), while Procter & Gamble Co trades at $150.94 (market cap $349.77B). The key difference: Procter & Gamble Co is far larger — about 201× Nuvation Bio Inc. Class A Common Stock's market cap, and Procter & Gamble Co pays a 2.89% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Procter & Gamble Co for 131 Days on average.
| NUVB | PG | |
|---|---|---|
Market Cap | $1.74B | $349.77B |
Volume | 9,289,619 | 10,055,825 |
Sector | Health | Consumer Staples |
52-Week High | $9.54 | $167.18 |
52-Week Low | $3.41 | $138.10 |
Typical Hold Time | 0 Days | 131 Days |
Enterprise Value | $1.33B | $375.61B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Procter & Gamble (PG) trades at $150.87, up 2.06% today, showing strong momentum near its consensus price target of $160.13. The stock maintains a bullish technical outlook with moving averages supporting upward momentum, while fundamentals reveal consistent earnings beats and robust profitability with 18.44% net margins. Recent corporate developments include a new WNBA partnership and a $1.09 dividend declaration, reinforcing its stable income appeal.
PG offers reliable growth with three consecutive earnings beats and strong cash flow generation, though premium valuation multiples pose near-term risk. The company's supply chain enhancements and dividend track record provide stability, but investors face headwinds from soft demand concerns and elevated P/E ratios. Wall Street maintains a bullish stance with 53% buy ratings, suggesting moderate upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
